News & Updates
Filter by Specialty:

Second-line tislelizumab + anlotinib + chemo shows potential to improve ES-SCLC survival
A treatment regimen combining tislelizumab, anlotinib, and two cycles of irinotecan in the second-line setting demonstrates favourable efficacy and safety in patients with extensive-stage small cell lung cancer (ES-SCLC), according to the results of the single-arm phase II ESTAIL study.
Second-line tislelizumab + anlotinib + chemo shows potential to improve ES-SCLC survival
19 Oct 2024
AI tool reads histology slides to predict lung cancer mutations
DeepGEM, a novel tool that harnesses artificial intelligence (AI), delivers accurate, timely, and economical gene mutation prediction from routinely acquired histology slides, enhancing the efficiency of lung cancer mutation screening, according to a study.
AI tool reads histology slides to predict lung cancer mutations
18 Oct 2024
Metastatic prostate cancer risk low in older men nearing age limit for PSA screening
Older men who have had prostate-specific antigen (PSA) testing and are approaching the age limit for recommended screening appear to have a relatively low risk of developing metastatic or fatal prostate cancer, suggests a recent study.
Metastatic prostate cancer risk low in older men nearing age limit for PSA screening
16 Oct 2024
Music a perioperative aide for lung cancer patients?
Individuals with resectable stage IA to IIIB non-small cell lung cancer (NSCLC) who plan to receive minimally invasive lung surgery may benefit from intensity-based personalized music therapy (IBP-MT) suggests the phase II Music of Lung Health II study.